clinical trial

[NGM Biopharmaceuticals, Inc.] NGM Biopharmaceuticals, Inc. announced it has dosed the first patient in a Phase I/Ib clinical trial of NGM831, an antagonist antibody product candidate designed to block the interaction of ILT3 with fibronectin, a key component of the tumor stroma, for the treatment of patients with advanced solid tumors.

[Kyodo News] A Japanese university research team has concluded that the world's first clinical trial, spanning over years, transplanting corneal tissues derived from induced pluripotent stem cells, or iPS cells, into four almost-blind patients was safe and effective.

[BMJ Open] Researchers tested the safety, tolerability and efficacy of human umbilical cord MSCs for the treatment of pneumonia induced sepsis through a single-centre, randomised single-blind parallel group, placebo-controlled trial.

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.

[Nature] Researchers in a pivotal African clinical trial have been denied access to a key COVID-19 antiviral drug, frustrating efforts to test the treatment in African populations and in combination with therapies that could potentially expand its utility on the continent.

[Genprex, Inc.] Genprex, Inc. announced the opening for patient enrollment of its Acclaim-2 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Keytruda® in patients with late-stage non-small cell lung cancer whose disease progressed after treatment with Keytruda.